Find a Commonwealth Resource
Cosibelimab
HealthData.Gov
Updated Mar 25, 2026
About this dataset
UNLOXCYT (cosibelimab) is a monoclonal antibody that blocks PD-L1 to help the immune system fight cancer cells. It's given as an intravenous injection, with each vial containing 300 mg in 5 mL. Manufactured by Checkpoint Therapeutics, Inc., it's approved for prescription use. This information was generated using AI and is provided for informational and research purposes only.
Data and resources (1)
- HTML
Cosibelimab
Access the FDA dataset for Cosibelimab — ANDA 203308 submitted by Mylan Institutional LLC
Modified Dec 27, 2025